Baba, H., Yamada, Y., Takahari, D., Matsumoto, H., Yoshida, K., Nakamura, M., . . . Sugihara, K. (2017). S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: Updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. ESMO Open.
Citação norma ChicagoBaba, Hideo, et al. "S-1 and Oxaliplatin (SOX) Plus Bevacizumab Versus MFOLFOX6 Plus Bevacizumab As First-line Treatment for Patients With Metastatic Colorectal Cancer: Updated Overall Survival Analyses of the Open-label, Non-inferiority, Randomised Phase III: SOFT Study." ESMO Open 2017.
MLA citiranjeBaba, Hideo, et al. "S-1 and Oxaliplatin (SOX) Plus Bevacizumab Versus MFOLFOX6 Plus Bevacizumab As First-line Treatment for Patients With Metastatic Colorectal Cancer: Updated Overall Survival Analyses of the Open-label, Non-inferiority, Randomised Phase III: SOFT Study." ESMO Open 2017.